Estradiol/progestogen vaginal - Warner Chilcott

Drug Profile

Estradiol/progestogen vaginal - Warner Chilcott

Alternative Names: Estradiol/progestogen intravaginal ring; Estradiol/progestogen IVR

Latest Information Update: 05 Dec 2007

Price : $50

At a glance

  • Originator Warner Chilcott
  • Class Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 16 Aug 2004 No development reported - Phase-II for Menopausal syndrome in United Kingdom (Vaginal)
  • 25 Jun 2004 Galen Holdings is now called Warner Chilcott
  • 17 Jan 2000 Phase-II clinical trials for Menopausal syndrome in United Kingdom (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top